Barclays reduced Medline’s price target amid inflationary pressures and near-term valuation concerns while maintaining an Overweight rating.
Barclays lowered its price target for Medline Inc. (NASDAQ:MDLN) to $45 from $50, citing inflationary pressures on margins and reduced upside to fiscal Q1 estimates. The firm maintained an Overweight rating, stating the stock’s valuation has become more attractive following recent secondary offerings.
Prior to the cut, Barclays had set a $50 target, while Tigress Financial raised its target to $62 from $60 in May. Tigress highlighted Medline’s transition to an AI-enabled supply chain as a long-term opportunity despite near-term disruptions.
Medline provides medical-surgical products and supply chain solutions, operating through its Medline Brand and Supply Chain Solutions segments.